Y Intercept Hong Kong Ltd Purchases New Shares in Evolus, Inc. (NASDAQ:EOLS)

Y Intercept Hong Kong Ltd purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 37,361 shares of the company's stock, valued at approximately $449,000. Y Intercept Hong Kong Ltd owned 0.06% of Evolus as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. IFP Advisors Inc grew its stake in shares of Evolus by 99.0% during the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock valued at $113,000 after purchasing an additional 4,691 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Evolus during the 4th quarter valued at approximately $106,000. Rafferty Asset Management LLC bought a new position in shares of Evolus during the 4th quarter valued at approximately $115,000. Quantbot Technologies LP bought a new position in shares of Evolus during the 4th quarter valued at approximately $118,000. Finally, Man Group plc bought a new position in shares of Evolus during the 4th quarter valued at approximately $121,000. 90.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on EOLS shares. HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. BTIG Research started coverage on Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $23.75.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 111,323 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $10.05, for a total value of $1,118,796.15. Following the completion of the transaction, the insider directly owned 381,509 shares in the company, valued at $3,834,165.45. This represents a 22.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Albert G. White III purchased 20,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was acquired at an average price of $9.45 per share, with a total value of $189,000.00. Following the completion of the purchase, the director directly owned 50,378 shares in the company, valued at $476,072.10. This trade represents a 65.84% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 153,571 shares of company stock valued at $1,537,090. 5.90% of the stock is owned by company insiders.

Evolus Price Performance

EOLS stock traded up $0.08 during midday trading on Friday, hitting $9.00. The company's stock had a trading volume of 761,211 shares, compared to its average volume of 942,004. Evolus, Inc. has a 12 month low of $8.65 and a 12 month high of $17.82. The company has a quick ratio of 2.16, a current ratio of 2.34 and a debt-to-equity ratio of 22.00. The firm has a market capitalization of $580.00 million, a price-to-earnings ratio of -10.11 and a beta of 0.97. The company has a 50 day moving average of $9.48 and a two-hundred day moving average of $11.27.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.